Ardelyx Inc ARDX

$3.10 0.00 (—)

Valuation

Market cap
772,483,000
Revenue TTM
$407,320,000
Net income TTM
$-61,600,000
PE ratio
0.00
Forward PE
—
Profit margin
-15.12%
Debt to equity
1.69

Trading

Volume
2,549,700
Avg volume
4,205,974
Day's range
$3.08 – $3.16
Shares out
249,188,000
Stochastic %K
49%
Beta
0.68
Analysts
Strong Sell
Price target
$12.80

Price

Company profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, I...

Show more

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
510 745 1700
Website
https://www.ardelyx.com
Address
400 Fifth Avenue, Suite 210, Waltham, United States

Latest news

Stocktwits

crypto_biotech Oct 30, 10:49 AM
$ARDX Bernie Baruch has been dead since 1965, which means every post he drops is technically a séance. And what does the séance produce? Not wisdom. Not market insight. A screenshot of AbbVie cutting Linzess in half, framed like he cracked the Enigma code. The man traded through two World Wars and his estate’s final act is narrating a fifty percent price cut on a constipation drug like it’s a hostile takeover. He didn’t even add analysis. No “here’s what this means for net price realization.” No “payer mix shift deserves a second look.” Just the numbers, bolded, and “just saying” the verbal equivalent of a mic drop from someone who can’t hold a microphone. That’s the part that should worry you. Not that a dead guy has opinions. That the opinions are this thin and still travel. Raab needs a solid beat or Bernie shifts the goalposts again. A new narrative. I still have skin in the game as do close friends, but we are all realists. Solid beat or Raab asked to leave.
0 replies
Burning_Cash Oct 30, 10:16 AM
$ARDX Big Tech’s AI fairytale is finally starting to collide with reality. Hopefully, commercial stage biotech can grab some of those investment dollars. We have actual products, patents and (a clear road to) profitability.
0 replies
bernardbaruch Oct 30, 1:43 AM
$ARDX I think @donkeykongreturns was spot on when it comes to you. Disingenuous vibe big time. He doesn’t want to read your comments anymore. Bad for his mojo. I told you before the same thing. You put out a smell factor. He’s a serious thinker /thesis developer and he generously shares in real time. You’re out. But you don’t need his thoughts so it doesn’t matter. Somebody shorted puts on 20 mm shares in a falling market or bought the 4’s and sold the 3’s Somebody else took the other side of those trades. Lots of psyops around that kind of action.
3 replies
bernardbaruch Oct 29, 10:11 PM
$ARDX Abbvie cut the price of Linzess in 1/2 going into 2026. They guided after Q2 to a 1/3 revenue increase. That’s the go to drug in IBS-C that we have built our market on by basically slipstreaming on their advertising efforts. “Full-year context: • 2024: ~$916M U.S. net sales • 2025: ~$865M • 2026 guidance (raised after Q2): $1.15–1.20 billion (driven by better net price + mid-single-digit demand growth) “Price” of the Drug List price / Wholesale Acquisition Cost (WAC) per 30-capsule bottle (all strengths): • Through end of 2025: ~$568 (specifically cited as $567.97) • Effective January 1, 2026: reduced to $282.48 (~50% cut)” Just saying…
1 replies
imlivinit Oct 29, 9:06 PM
$ARDX How is it that millions of shares can be traded and end the day with zero price change?
2 replies
aljudaia92 Oct 29, 5:50 PM
$ARDX Let's not forget that many companies, like Phathom Pharmaceuticals ($PHAT), faced similar insurance reimbursement hurdles and successfully addressed them. Look at VOQUEZNA's quarterly sales in 2026: $58.5M in Q1, $74.3M in Q2, and $84.7M in Q3. This shows that insurance friction can be overcome, and I believe $ARDX has a real opportunity to follow a similar path.
2 replies
opportoni Oct 29, 5:18 PM
$ARDX Can we get a green week for a change ffs?
0 replies
opportoni Oct 29, 4:01 PM
$ARDX Not the best reference today…
2 replies